Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CR-001

PreclinicalSmall molecule

CCrescent Biopharma, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced/metastatic Solid TumorsRecruiting

Locally Advanced/metastatic Solid TumorsPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Locally Advanced/metastatic Solid Tumors

NCT07335497

Clinical

Trials by Indication[1]

Locally Advanced/Metastatic Solid Tumors1 trial

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting·CCrescent Biopharma, Inc.·Preclinical·NCT07335497·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CR-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CR-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CR-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Crescent Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCrescent Biopharma, Inc.

Related News